LNTH Quote, Financials, Valuation and Earnings

Day One Biopharmaceuticals, Inc. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of -49.57%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat Day One Biopharmaceuticals, Inc.'s return on equity of -30.98%.

Lantheus Holdings, Inc. has a consensus price target of $80.93, signalling upside risk potential of 30.8%. On the other hand Day One Biopharmaceuticals, Inc. has an analysts' consensus of $22.25 which suggests that it could grow by 166.79%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than Lantheus Holdings, Inc..

Lantheus Holdings, Inc. has a beta of -0.102, which suggesting that the stock is 110.17% less volatile than S&P 500. In comparison Day One Biopharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Day One Biopharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. Day One Biopharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Lantheus Holdings, Inc. quarterly revenues are $384M, which are larger than Day One Biopharmaceuticals, Inc. quarterly revenues of $39.8M. Lantheus Holdings, Inc.'s net income of $27.8M is higher than Day One Biopharmaceuticals, Inc.'s net income of -$19.7M. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 25.98x while Day One Biopharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 2.82x versus 6.40x for Day One Biopharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Iovance Biotherapeutics, Inc. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of -135.28%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.

Lantheus Holdings, Inc. has a consensus price target of $80.93, signalling upside risk potential of 30.8%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 275%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Lantheus Holdings, Inc..

Lantheus Holdings, Inc. has a beta of -0.102, which suggesting that the stock is 110.17% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.

Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Lantheus Holdings, Inc. quarterly revenues are $384M, which are larger than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Lantheus Holdings, Inc.'s net income of $27.8M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 25.98x while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 2.82x versus 2.91x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Travere Therapeutics, Inc. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of 15.59%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat Travere Therapeutics, Inc.'s return on equity of -263.9%.

Lantheus Holdings, Inc. has a consensus price target of $80.93, signalling upside risk potential of 30.8%. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $41.5000 which suggests that it could grow by 17.46%. Given that Lantheus Holdings, Inc. has higher upside potential than Travere Therapeutics, Inc., analysts believe Lantheus Holdings, Inc. is more attractive than Travere Therapeutics, Inc..

Lantheus Holdings, Inc. has a beta of -0.102, which suggesting that the stock is 110.17% less volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.435%.

Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.

Lantheus Holdings, Inc. quarterly revenues are $384M, which are larger than Travere Therapeutics, Inc. quarterly revenues of $164.9M. Lantheus Holdings, Inc.'s net income of $27.8M is higher than Travere Therapeutics, Inc.'s net income of $25.7M. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 25.98x while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 2.82x versus 7.36x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenetic Biosciences, Inc. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of -49.65%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat Xenetic Biosciences, Inc.'s return on equity of -59.39%.

Lantheus Holdings, Inc. has a consensus price target of $80.93, signalling upside risk potential of 30.8%. On the other hand Xenetic Biosciences, Inc. has an analysts' consensus of -- which suggests that it could grow by 1474.8%. Given that Xenetic Biosciences, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than Lantheus Holdings, Inc..

Lantheus Holdings, Inc. has a beta of -0.102, which suggesting that the stock is 110.17% less volatile than S&P 500. In comparison Xenetic Biosciences, Inc. has a beta of 2.398, suggesting its more volatile than the S&P 500 by 139.837%.

Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenetic Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. Xenetic Biosciences, Inc. pays out -- of its earnings as a dividend.

Lantheus Holdings, Inc. quarterly revenues are $384M, which are larger than Xenetic Biosciences, Inc. quarterly revenues of $1M. Lantheus Holdings, Inc.'s net income of $27.8M is higher than Xenetic Biosciences, Inc.'s net income of -$509.9K. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 25.98x while Xenetic Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 2.82x versus 1.37x for Xenetic Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.